MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- AJANTA PHARMA - TEVA PHARMA (Israel)
AJANTA PHARMA vs TEVA PHARMA (Israel) - Comparison Results
TEVA PHARMA (Israel)
Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
Financials
 AJANTA PHARMA  TEVA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| AJANTA PHARMA Mar-19 |
TEVA PHARMA Dec-13 |
AJANTA PHARMA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,422 | 3,088 | - | |
| Low | Rs | 898 | 2,683 | - | |
| Sales per share (Unadj.) | Rs | 233.5 | 1,772.2 | - | |
| Earnings per share (Unadj.) | Rs | 44.0 | 110.7 | - | |
| Cash flow per share (Unadj.) | Rs | 52.2 | 254.0 | - | |
| Dividends per share (Unadj.) | Rs | 9.00 | 96.91 | - | |
| Dividend yield (eoy) | % | 0.8 | 3.4 | 23.1% | |
| Book value per share (Unadj.) | Rs | 255.1 | 1,968.6 | - | |
| Shares outstanding (eoy) | m | 88.02 | 848.00 | - | |
| Bonus/Rights/Conversions | BB | - | - | ||
| Price / Sales ratio | x | 5.0 | 1.6 | 305.1% | |
| Avg P/E ratio | x | 26.4 | 26.1 | 101.2% | |
| P/CF ratio (eoy) | x | 22.2 | 11.4 | 195.7% | |
| Price / Book Value ratio | x | 4.5 | 1.5 | 310.2% | |
| Dividend payout | % | 20.5 | 87.5 | 23.4% | |
| Avg Mkt Cap | Rs m | 102,081 | 2,446,667 | 4.2% | |
| No. of employees | `000 | 6.8 | 44.9 | 15.1% | |
| Total wages/salary | Rs m | 4,307 | 0 | - | |
| Avg. sales/employee | Rs Th | 3,022.6 | 33,437.1 | 9.0% | |
| Avg. wages/employee | Rs Th | 633.4 | 0 | - | |
| Avg. net profit/employee | Rs Th | 569.1 | 2,088.8 | 27.2% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 20,554 | 1,502,830 | 1.4% | |
| Other income | Rs m | 211 | 0 | - | |
| Total revenues | Rs m | 20,765 | 1,502,830 | 1.4% | |
| Gross profit | Rs m | 5,664 | 411,551 | 1.4% | |
| Depreciation | Rs m | 721 | 121,475 | 0.6% | |
| Interest | Rs m | 12 | 29,518 | 0.0% | |
| Profit before tax | Rs m | 5,143 | 260,558 | 2.0% | |
| Minority Interest | Rs m | 0 | 1,184 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -171,042 | 0.0% | |
| Tax | Rs m | 1,273 | -3,181 | -40.0% | |
| Profit after tax | Rs m | 3,870 | 93,881 | 4.1% | |
| Gross profit margin | % | 27.6 | 27.4 | 100.6% | |
| Effective tax rate | % | 24.8 | -1.2 | -2,027.5% | |
| Net profit margin | % | 18.8 | 6.2 | 301.4% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 11,812 | 1,015,006 | 1.2% | |
| Current liabilities | Rs m | 3,776 | 885,171 | 0.4% | |
| Net working cap to sales | % | 39.1 | 8.6 | 452.5% | |
| Current ratio | x | 3.1 | 1.1 | 272.8% | |
| Inventory Days | Days | 77 | 91 | 85.2% | |
| Debtors Days | Days | 82 | 96 | 85.1% | |
| Net fixed assets | Rs m | 14,398 | 490,857 | 2.9% | |
| Share capital | Rs m | 175 | 3,699 | 4.7% | |
| Net worth | Rs m | 22,452 | 1,669,359 | 1.3% | |
| Long term debt | Rs m | 7 | 768,430 | 0.0% | |
| Total assets | Rs m | 26,962 | 3,434,448 | 0.8% | |
| Interest coverage | x | 444.3 | 9.8 | 4,521.6% | |
| Debt to equity ratio | x | 0 | 0.5 | 0.1% | |
| Sales to assets ratio | x | 0.8 | 0.4 | 174.2% | |
| Return on assets | % | 14.4 | 3.6 | 400.7% | |
| Return on equity | % | 17.2 | 5.6 | 306.5% | |
| Return on capital | % | 23.0 | 4.9 | 465.4% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 3,748 | 239,473 | 1.6% | |
| From Investments | Rs m | -2,228 | -84,855 | 2.6% | |
| From Financial Activity | Rs m | -1,475 | -287,264 | 0.5% | |
| Net Cashflow | Rs m | 45 | -132,646 | -0.0% | |
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 73.98 Rs / USD
Compare AJANTA PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare AJANTA PHARMA With: NOVARTIS IPCA LABS DIVIS LABORATORIES LUPIN DR. REDDYS LAB
Today's Market
Nifty is Weak but Smallcaps Can Outperform(Momentum Moves)
The market see-sawed during the week with both the bulls and bears swinging it out. But in the end, it was the bears who won. The Nifty ended the day, the week, and the month at 14,529.15.
Related Views On News
AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)
Feb 5, 2021 | Updated on Feb 5, 2021For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)
Nov 6, 2020 | Updated on Nov 6, 2020For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Jun 24, 2019 | Updated on Jun 24, 2019Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.
More Views on NewsMost Popular
It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)
Feb 24, 2021Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
Intraday Trading for a Living (Fast Profits Daily)
Feb 15, 2021In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
Top 5 Stocks Mutual Funds Bought and Sold in January 2021 (Sector Info)
Feb 16, 2021A look at what India's top equity mutual funds bought and sold in January 2021.
I Would Recommend this Small-cap Stock Over Tesla (Profit Hunter)
Feb 16, 2021Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More
